NEW YORK (GenomeWeb News) – Epigenomics today reported a 6 percent increase year over year in third-quarter revenues.

The Berlin, Germany-based firm said that for the three months ended Sept. 30 revenues totaled €272,000 ($347,000), up from €257,000 a year ago as an increase in R&D service fees offset a decrease in licensing revenues.

Epigenomics' net loss narrowed to €3.7 million, or €.42 per share, compared to a net loss of €4.8 million, or €.55 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.